Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Personalized Medicine Shows Extended Reach Throughout Breast Cancer

November 18th 2021

Molecular markers, risk, and response are being used to better tailor escalated and de-escalated treatment approaches for women with breast cancer.

Dr. Toppmeyer on the Utility of De-Escalation Trials in HER2+ Breast Cancer

November 18th 2021

Deborah L. Toppmeyer, MD, discusses the utility of clinical trials evaluating de-escalated treatment approaches in HER2-positive breast cancer.

Dr. Toomey on the Importance of De-Escalation Clinical Trials in HER2+ Breast Cancer

November 18th 2021

Kathleen C. Toomey, medical oncologist, discusses the importance of clinical trials evaluating de-escalated treatment strategies in HER2-positive breast cancer.

Progress Made Across Breast Cancer Paradigm Sets the Stage for Improved Sequencing and Future Research

November 18th 2021

Sarah Sammons, MD, discusses key advances made across the spectrum of breast cancer, including HER2-positive, hormone receptor–positive, and triple-negative disease, as well as key data that have reshaped these paradigms.

Sacituzumab Govitecan Meets ORR End Point in Chinese Patients With Metastatic TNBC

November 17th 2021

Sacituzumab govitecan-hziy significantly improved overall response rate in Chinese patients with metastatic triple-negative breast cancer.

Investigators Aim to Identify New Treatment Targets with Cancer Cell Map Initiative

November 16th 2021

The Cancer Cell Map Initiative, developed by investigators at the University of California San Francisco and the University of California San Diego, has successfully charted how hundreds of genetic mutations involved in breast cancer and cancers of the head and neck affect the activity of proteins that ultimately lead to disease.

ESMO 2021: Updates in Triple Negative Breast Cancer

November 15th 2021

Drs Joyce O’Shaughnessy, Sara Tolaney, Sara Hurvitz, and Mark Pegram examine recent trial data from ESMO 2021 on triple-negative breast cancer.

Dr. Falkson on the Potential to De-Escalate Chemotherapy in HER2+ Breast Cancer

November 12th 2021

Carla Falkson, MBChB, MMed, MD, discusses the potential to de-escalate chemotherapy in HER2-positive breast cancer.

Eftilagimod Alpha/Paclitaxel Combo Shows Improved OS in Metastatic HR+ Breast Cancer Subsets

November 12th 2021

The combination of eftilagimod alpha and paclitaxel produced a modest increase in median overall survival in patients with endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer. Though, the effects were significant in patients younger than 65 years old, had low monocytes, or had more aggressive disease.

Gradishar Gives Insight Into the Growing Role of SERDs in Breast Cancer

November 11th 2021

Dr. Gradishar discusses the evolution of SERDs in breast cancer, novel SERDs that could shift the paradigm of breast cancer treatment, and ongoing research that could solidify the role of these agents in the field.

Dr. Kimmick on the Results of the ATEMPT Trial in Early-Stage HER2+ Breast Cancer

November 9th 2021

Gretchen G. Kimmick, MD, MS, discusses the results of the phase 2 ATEMPT trial in early-stage HER2-positive breast cancer

Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial

November 8th 2021

Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.

Leronlimab Continues to Demonstrate Early Promise in CCR5+ Metastatic TNBC

November 4th 2021

Leronlimab was found to improve survival in patients with CCR5-positive metastatic triple-negative breast cancer in whom at least 2 prior lines of therapy had failed, according to data from an updated analysis of a Compassionate Use Study, a phase 1b/2 study, and from a basket study.

ESMO Guidelines Recommend Personalized Treatment and Multidisciplinary Decision Making in Breast Cancer

November 4th 2021

ESMO Clinical Practice Guidelines indicate that the management of metastatic breast cancer requires nuanced and multidisciplinary decision making to optimize and personalize locoregional, systemic, and supportive care.

Breast Cancer Paradigm Moves Toward Less Morbid Treatments With Improved Risk Assessment and Imaging Strategies

November 3rd 2021

Paul Lawrence Baron, MD, discussed best practices for determining a patient’s risk of developing breast cancer, the significance of targeting HER2 in patients with early-stage and metastatic disease, and remaining questions with radiation therapy in the field.

Dr. Baron on Contributing Factors for Developing Breast Cancer

November 2nd 2021

Paul Lawrence Baron, MD, discusses contributing factors for developing breast cancer.

A Dynamic Treatment Landscape Emerges for Early-Stage TNBC

November 2nd 2021

Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.

Interesting Trials in HER2+ Breast Cancer

November 1st 2021

Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.

Optimizing the Management of ILD: Take-Home Messages

October 29th 2021

Experts highlight key messages regarding optimal identification and management of interstitial lung disease.

CoopERA Results Show Benefits of Giredestrant in ER+/HER2– Early Breast Cancer

October 28th 2021

Sara Hurvitz, MD, discusses the coopERA study and how these data, along with findings from other clinical trials, could lead to significant changes in treatment for patients with ER-positive/HER2-negative breast cancer.